Search

Displaying results 2001 - 2010 of 8006 in total
  1. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … [L36000] It was later approved for the treatment of locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) in patients aged 12 years and older.[L49271]

  2. Drug

    Aminohippuric acid

    go.drugbank.com/drugs/DB00345
    ApprovedInvestigationalWithdrawn

    Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

    Categories: Tests for Renal Function and Ureteral Injuries, Compounds used in a research, industrial, or household setting
  3. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.

  4. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7, … TrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

  5. Drug

    Helium

    go.drugbank.com/drugs/DB09155
    ApprovedInvestigationalVet approved

    Its clinical benefit in inhalation therapy arises from its advantageous physical properties than ambient air.

  6. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride. … Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity.

  7. Drug

    Lodoxamide

    go.drugbank.com/drugs/DB06794
    Approved

    Lodoxamide is a mast-cell stabilizer for topical administration into the eye. … Lodoxamide is marketed under the brand name Alomide by Alcon.

  8. Drug

    Amyl Nitrite

    go.drugbank.com/drugs/DB01612
    Approved

    Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use.

  9. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection. … Vosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection [FDA Label].

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]